Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: <i>in vitro</i> characterization, stability, <i>in vitro</i> cytotoxicity, and antiviral activity using real time cell analysis
Ayca Yıldız-Peköz, Özlem Akbal Dağıstan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Müge Serhatlı, Gamze Çakırca, Şaban Teki̇n, S. Sen, Mustafa Sevım, Lütfiye Mülazımoğlu, Berrak C. Yegen
Abstract
aerodynamic profiles of the developed inhaled favipiravir formulation, when delivered with soft-mist inhaler indicated good lung targeting properties. These results suggest that favipiravir solution prepared with PBS could be considered as a suitable and promising inhalation formulation for pulmonary delivery in the treatment of patients with COVID-19.
Topics & Concepts
FavipiravirVero cellPharmacologyInhalationIn vitroToxicityMedicineChemistryVirusVirologyCoronavirus disease 2019 (COVID-19)AnesthesiaBiochemistryOrganic chemistryInfectious disease (medical specialty)PathologyDiseaseInhalation and Respiratory Drug DeliveryRespiratory viral infections researchSARS-CoV-2 and COVID-19 Research